Effect of Bifidobacterium Triple Viable Capsule in the Treatment of Non-alcoholic Fatty Liver Disease

MA Ruihong; HUANG Yingqi

doi:10.3969/j.issn.1672-7185.2019.11.022

Abstract：Objective? To explore the effect of bifidobacterium triple viable capsule in the treatment of non-alcoholic fatty liver. Methods A total of 120 cases of non-alcoholic fatty liver patients admitted to Bengang General Hospital of Liaoning Health Industry Group from January 2017 to December 2018 were randomly divided into observation group and control group, 60 cases in each group. The control group was treated with non-drug intervention combined with hepatoprotective therapy, and the observation group was treated with bifidobacterium triple viable capsule on the basis of the control group. The therapeutic effects of the two groups were compared. Results The total effective rate of the observation group was 86.67%(52/60), higher than 68.33%(41/60) of the control group(χ2=5.783, P<0.05). After treatment, the indexes of blood lipid and liver function in the two groups were improved, and the indexes of blood lipid and liver function in the observation group were significantly better than those in the control group(P<0.05). The incidence of adverse reactions in the control group was 6.67%(4/60), lower than that in the observation group 10.00%(6/60), but there was no significant difference between the two groups(χ2=0.436, P>0.05). Conclusion The bifidobacterium triple viable capsule can improve the curative effect, liver function and blood lipid level, and will not increase the incidence of adverse reactions in the treatment of non-alcoholic fatty liver, which is worthy of clinical application.